News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellular Biomedicine Group (CBMG)'s Stock Price Quadruples In Two Months


8/18/2014 9:14:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

August 15, 2014 -- On Monday, August 18, Dr. William Cao, CEO of Cellular Biomedicine Group will ring the closing bell at NASDAQ to celebrate CBMG's recent listing on the exchange. CBMG is a US-headquartered biotech that is developing new treatments for degenerative diseases and cancer in China. The NASDAQ event caps a busy two months for CBMG. During that time, the company reported positive data from a trial of its knee arthritis treatment, jettisoned its consulting business, raised $10 million in a private placement, paid $23 million to acquire a China cellular products company – and the company's stock price rose from below $6 to $23.

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES